Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an…
GA Depot
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
Recommended Posts
- One silent MRI lesion may be enough to consider stronger MS treatment
- It may only be one life with multiple sclerosis, but it’s mine
- Certain cannabis-based therapies may help relieve spasticity in MS
- Greater disability tied to poorer cognitive function in people with RRMS
- FDA OKs first clinical trial testing novel oral therapy in MS patients